» Articles » PMID: 26767525

Abuse Potential of Pregabalin: A Systematic Review

Overview
Journal CNS Drugs
Specialties Neurology
Pharmacology
Date 2016 Jan 16
PMID 26767525
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Several case reports and epidemiological studies have raised concern about the abuse potential of pregabalin, the use of which has increased substantially over the last decade. Pregabalin is, in some cases, used for recreational purposes and it has incurred attention among drug abusers for causing euphoric and dissociative effects when taken in doses exceeding normal therapeutic dosages or used by alternative routes of administration, such as nasal insufflation or venous injection. The magnitude of the abuse potential and the mechanism behind it are not fully known.

Objective: The aim of this study was to present a systematic review of the data concerning the abuse potential of pregabalin.

Methods: We performed a systematic literature search and reviewed the preclinical, clinical and epidemiological data on the abuse potential of pregabalin.

Results: We included preclinical (n = 17), clinical (n = 19) and epidemiological (n = 13) studies addressing the abuse potential of pregabalin. We also reviewed case reports (n = 9) concerning abuse of pregabalin. The preclinical studies indicated that pregabalin possesses modulatory effects on the GABA and glutamate systems, leaving room for an abuse potential. Further, clinical studies reported euphoria as a frequent side effect in patients treated with pregabalin. The majority of case reports concerning abuse of pregabalin involved patients with a history of substance abuse and, similarly, epidemiological studies found evidence of abuse, especially among opiate abusers.

Conclusions: Overall, the available literature suggests an important clinical abuse potential of pregabalin and prescribers should pay attention to signs of abuse, especially in patients with a history of substance abuse.

Citing Articles

Silexan in anxiety, depression, and related disorders: pharmacological background and clinical data.

Kasper S, Eckert A Eur Arch Psychiatry Clin Neurosci. 2024; .

PMID: 39453446 DOI: 10.1007/s00406-024-01923-8.


Characteristics of Non-Therapeutic Pregabalin Users Detected by a Community Pharmacies Network in a Region of Southern Europe.

Perello M, Rio-Aige K, Rius P, Perez-Cano F, Rabanal M J Clin Med. 2024; 13(19).

PMID: 39408002 PMC: 11477447. DOI: 10.3390/jcm13195942.


Understanding pregabalin misuse and dependence: Insights from a North Indian addiction treatment center.

Ghosh A, Shukla S, Dhankar M, Naik S, Subodh B, Basu D Indian J Psychiatry. 2024; 66(8):723-728.

PMID: 39398509 PMC: 11469571. DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_307_24.


Systematic review: The relationship between gabapentinoids, etizolam, and drug related deaths in Scotland.

Ciesluk B, Inglis D, Parke A, Troup L PLoS One. 2024; 19(10):e0310655.

PMID: 39383139 PMC: 11463789. DOI: 10.1371/journal.pone.0310655.


Antineuropathic Pain Management After Orthopedic Surgery: A Systematic Review.

Harder T, Harder J, Baum G, Cox C, Harder J, Hernandez E Orthop Rev (Pavia). 2024; 16:93012.

PMID: 38505138 PMC: 10950197. DOI: 10.52965/001c.93012.


References
1.
Filipetto F, Zipp C, Coren J . Potential for pregabalin abuse or diversion after past drug-seeking behavior. J Am Osteopath Assoc. 2010; 110(10):605-7. View

2.
Baastrup C, Jensen T, Finnerup N . Pregabalin attenuates place escape/avoidance behavior in a rat model of spinal cord injury. Brain Res. 2010; 1370:129-35. DOI: 10.1016/j.brainres.2010.11.008. View

3.
Johannessen Landmark C, Fossmark H, Larsson P, Rytter E, Johannessen S . [The prescription registry and abuse of pregabalin]. Tidsskr Nor Laegeforen. 2011; 131(3):223. DOI: 10.4045/tidsskr.10.1328. View

4.
Guglielmo R, Martinotti G, Clerici M, Janiri L . Pregabalin for alcohol dependence: a critical review of the literature. Adv Ther. 2012; 29(11):947-57. DOI: 10.1007/s12325-012-0061-5. View

5.
Olesen S, Bouwense S, Wilder-Smith O, Goor H, Drewes A . Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial. Gastroenterology. 2011; 141(2):536-43. DOI: 10.1053/j.gastro.2011.04.003. View